Responses
Poster Presentation
Co-targeting of delta-like ligand 4 (DLL4) and vascular endothelial growth factor a (VEGF) with programmed death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses
Compose a Response to This Article
Other responses
No responses have been published for this article.